In one paragraphArticle in Nature genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
20 authors.
Lu Zeng *Center for Translational and Computational Neuroimmunology & Columbia Multiple Sclerosis Center, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9381-7690 Tsering LamaCenter for Translational and Computational Neuroimmunology & Columbia Multiple Sclerosis Center, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Jessy ChenCenter for Translational and Computational Neuroimmunology & Columbia Multiple Sclerosis Center, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
International Multiple Sclerosis Genetics Consortium
Tanuja ChitnisAnn Romney Center for Neurologic Diseases and Brigham Multiple Sclerosis Center, Department of Neurology, Brigham & Women's Hospital, Mass General Brigham, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9897-4422 Howard L WeinerAnn Romney Center for Neurologic Diseases and Brigham Multiple Sclerosis Center, Department of Neurology, Brigham & Women's Hospital, Mass General Brigham, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0203-9681 Stéphanie DebetteBordeaux Population Health Research Center, INSERM, UMR1219, University of Bordeaux, Bordeaux, France.
Gao WangThe Gertrude H. Sergievsky Center and the Department of Neurology, Columbia University, New York, NY, USA.
Masashi FujitaCenter for Translational and Computational Neuroimmunology & Columbia Multiple Sclerosis Center, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-1457-6233 Frauke ZippDepartment of Neurology, Research Center for Immunotherapy (FZI) and Focus Program Translational Neuroscience (FTN), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.ORCID http://orcid.org/0000-0002-1231-1928 Mariko TagaCenter for Translational and Computational Neuroimmunology & Columbia Multiple Sclerosis Center, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA.
Philip L De JagerCenter for Translational and Computational Neuroimmunology & Columbia Multiple Sclerosis Center, Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA. pld2115@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-8057-2505 Funding
Multi-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7MPredictive utility of polygenic risk scores for chronic kidney disease.K25DK128563 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KHAN, ATLAS · 2021 to 2025
$846kDeutsche Forschungsgemeinschaft (German Research Foundation) SFB/CRC 1292 (project number 318346496)National Multiple Sclerosis Society (National MS Society) BI-2408-43968U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) K25DK128563U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) U01 AG061356
6 · The paper itselfAbstract
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease. Previous genetic studies have identified susceptibility loci that primarily impact immune cells and microglia. Here we performed a multi-ancestry genome-wide association study of 20,831 MS cases and 729,220 controls and identified 236 susceptibility variants outside of the major histocompatibility complex, including four novel genomic loci. We also derived a polygenic score for MS; while optimized for European ancestry, it is informative for African American and Latino individuals. Integrating single-cell data from blood and brain tissue, we identified 76 candidate causal genes. Inhibitory neurons emerged as a key target cell type for MS-associated variants, with seven loci, including STAT3, displaying altered expression only in these cells. The STAT3 variant is also associated with cognition and white matter integrity in individuals with no MS and greater sNfL levels in individuals with MS, suggesting that MS susceptibility may reflect reduced central nervous system resilience to inflammatory challenges.
Indexed as
Genetic Predisposition to DiseaseGenome-Wide Association StudyMultiple SclerosisNeuronsCase-Control StudiesHumansMultifactorial InheritancePolymorphism, Single NucleotideSTAT3 Transcription FactorSTAT3 protein, humanSTAT3 Transcription Factor
What OpenQuestion holds
Textmetadata
Read underepoch 390